GlassScriptPhysician profile
Michael C Rockwell
NPI 1083655195
$6,864.78
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,184 · 2020: $562 · 2021: $1,079 · 2022: $1,659 · 2023: $1,285 · 2024: $1,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,380.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,610.01 | 2021-2024 | Vraylar |
| Sunovion Pharmaceuticals INC. | $1,022.84 | 2019-2022 | |
| Alkermes, INC. | $455.49 | 2021-2024 | Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $369.59 | 2019-2024 | Trintellix |
| Allergan, INC. | $353.70 | 2019-2020 | |
| Axsome Therapeutics, INC. | $317.41 | 2022-2024 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $297.64 | 2019-2022 | |
| Lundbeck LLC | $295.14 | 2019-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $279.30 | 2019-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $235.44 | 2019-2024 | Spravato |
| Supernus Pharmaceuticals, INC. | $227.02 | 2022-2023 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $211.97 | 2019-2024 | Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $198.96 | 2022-2024 | Caplyta |
| Bausch Health US, LLC | $149.49 | 2019-2023 | Aplenzin |
| Corium, LLC | $140.36 | 2022-2024 | Azstarys |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $109.88 | 2021-2022 | |
| Almatica Pharma LLC | $106.82 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $105.41 | 2022-2024 | Fanapt, Hetlioz |
| Merck Sharp & Dohme LLC | $94.35 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $89.38 | 2022-2024 | Quviviq |
| Shire North American Group INC | $66.48 | 2019 | |
| Jazz Pharmaceuticals INC. | $32.74 | 2021 | |
| Avanir Pharmaceuticals, INC. | $31.16 | 2019 | |
| Tris Pharma INC | $23.00 | 2023 | Dyanavel Xr |
| Alfasigma USA, INC. | $22.15 | 2021 | |
| Ironshore Pharmaceuticals INC. | $19.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rockwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.